K R Miao

Nanjing Medical University, Nan-ching, Jiangsu Sheng, China

Are you K R Miao?

Claim your profile

Publications (8)16.13 Total impact

  • K R Miao · Q Q Pan · H X Wu · X Y Zhou · M Pan · M Xue · S Fan · X Y Wang · X Zhao · R C Tang · C Y Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: We report here the unique sequence of a novel human leucocyte antigen (HLA)-C allele resulted in amplification of a product with a primer pair used in sequence-specific primer (SSP) HLA-B typing, which led subsequently to identification of a new allele of Cw*0339 by sequence-based typing method. This new allele is closely related to Cw*031101 with only two nucleotide changes from T to G at position 97, and T to C at position 105 in the exon 2 region of HLA-C locus. The first nucleotide substitution causes an amino acid alteration from tyrosine to aspartic acid at amino acid residue 9 (Y to D), while the second one keeps alanine at residue 11 unchanged. Most interestingly, the nucleotide change from T to G at position 97 makes it identical to the 3' end sequence of one SSP of the commercial HLA-B SSP typing kit we were using. In this specific case, it resulted in amplification of a product of HLA-C gene instead of B gene.
    No preview · Article · Jan 2009 · International Journal of Immunogenetics
  • H.R. Qiu · J.Y. Li · K.R. Miao · R Wang · W Xu

    No preview · Article · Aug 2008 · Cancer genetics and cytogenetics
  • K R Miao · Q Q Pan · R C Tang · X P Zhou · S Fan · XY Wang · X Zhao · M Xue · X Y Zhou · C Y Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: The polymorphism of human leucocyte antigen (HLA)-A, -B and -DRB1 genes and their computed haplotype analysis results from a population of Jiangsu province of China are presented here. The data consist of 20 248 unrelated peripheral blood stem cell donors in Jiangsu Branch of Chinese National Marrow Donor Program registry. In total, 18 different HLA-A alleles, 34 different HLA-B alleles and 13 different HLA-DRB1 alleles were found in Jiangsu Han population. The most frequent alleles in HLA-A, -B and -DRB1 loci were A*02 (29.55%), B*15 (14.40%), and DRB1*09 (16.15%), respectively. The most common haplotype in A-B-DRB1 loci was A*30-B*13- DRB1*07 (6.92%), in A-B loci was A*30-B*13 (8.05%), in B-DRB1 loci was B*13-DRB1*07 (8.17%), and in A-DRB1 loci was A*02-DRB1*09 (8.30%). The dendrogram study indicated that the distribution of HLA genes in Jiangsu Han population, as expected, represented a mixture of Northern and Southern Han population in China. These findings could shade new lights in population genetics and anthropology studies of Han-Chinese.
    No preview · Article · Jan 2008 · International Journal of Immunogenetics
  • K R Miao · Q Q Pan · M Xue · S Fan · X Y Wang · M Pan · X Y Zhou · X M Fei · X Zhao · C Y Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: Experimental studies using synthetic peptides identical to the bcr-abl fusion region in chronic myeloid leukemia (CML) patients have revealed that some specific peptides could bind to human leukocyte antigen (HLA) class I and class II molecules. Previous clinical observations have also reported some significant HLA associations with the development of CML in their populations. Due to high diversity of HLA alleles, the present study assessed the possibility of an association of HLA molecules in CML patients living in Jiangsu province, the eastern part of China. HLA-A, B and DRB1 allele distributions in 295 CML patients (aged 4-65 years) were analysed and compared with unrelated healthy hematopoietic stem cell donors from the same ethnic and geographic background. By comparison of the HLA gene distribution characteristics between CML and healthy donor populations, differences with statistical significance were found in HLA-A*30 (5.42% versus 9.13%) with odds ratio (OR) 0.57, DRB1*07 (8.14% versus 12.51%; OR = 0.62), and B*81 (0.51% versus 0.09%, OR = 5.44). These results suggest that expression of HLA-A*30, DRB1*07 might imply a protective effect on CML acquisition, while B*81 might be associated with CML susceptive factors in our population.
    No preview · Article · Dec 2007 · Leukemia and Lymphoma
  • X M Fei · Y.J. Wu · Z Chang · K R Miao · Y.H. Tang · X.Y. Zhou · L X Wang · Q Q Pan · C.Y. Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: The major challenge for cord blood transplantation (CBT) is higher rates of delayed and failed engraftment. In an attempt to broaden the application of CBT to more candidates, ex vivo expansion of hematopoietic stem/progenitor cells in CB is a major area of investigation. The purpose of this study was to employ human BM mesenchymal stromal cells (hBM-MSC) as the feeding-layer to expand CB cells ex vivo. In this study, hBM-MSC were isolated and characterized by morphologic, mmunophenotypic and RT-PCR analysis. The hBM-MSC at passage 3 were employed as the feeding-layer to expand CB CD34(+) cells in vivo in the presence of thrombopoietin, flt3/flk2 ligand, stem cell factor and G-CSF. The repopulating capacity of the ex vivo-expanded CB cells was also evaluated in a NOD/SCID mice transplant experiment. After 1 or 2 weeks of in vitro expansion, hBM-MSC supported more increasing folds of CB in total nucleated cells, CD34(+) cells and colony-forming units (CFU) compared with CB without hBM-MSC. Furthermore, although NOD/SCID mice transplanted with CB cells expanded only in the presence of cytokines showed a higher percentage of human cell engraftment in BM than those with unexpanded CB CD34(+) cells, expanded CB cells co-cultured with hBM-MSC were revealed to enhance short-term engraftment further in recipient mice. Our study suggests that hBM-MSC enhance in vitro expansion of CB CD34(+) cells and short-term engraftment of expanded CB cells in NOD/SCID mice, which may be valuable in a clinical setting.
    No preview · Article · Feb 2007 · Cytotherapy
  • K R Miao · M Xue · XY Zhou · R Xu · X M Fei · Q Q Pan · J W Zhang · X Zhao · S Fan · D KuKuruga · AL Xu · CY Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: We report here a novel human leukocyte antigen (HLA) allele, DRB1*1449, in the Han-Chinese population. The nature of the new allele was confirmed by the sequencing-based typing (SBT) method. Genomic DNA and six subclones containing DNA fragment of DRB1 exon 2 were sequenced in both forward and reverse directions. The exon 2 nucleotide sequence of DRB1*1449 is closely related to DRB1*1432 allele based on sequence homology. It has four nucleotide (nt) substitutions at positions 71, 196, 244 and 245 in exon 2, which lead to changes of amino acid sequences. The serological assignment of DRB1*1449 is DR14 based on the serological HLA typing result. This novel allele might be a result of recombination between DRB1*1402 and DRB1*140101 like alleles, which are very common among Chinese population.
    No preview · Article · Mar 2006 · International Journal of Immunogenetics
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel human leucocyte antigen-DRB1*16 (HLA-DRB1*16) allele (DRB1*1609) has been identified by sequencing-based typing (SBT) in Chinese Han population. This new allele has identical nucleotide sequence to DRB1*160101 in exon 2, except for a single-nucleotide substitution from A to T at position 127. This change leads to an amino acid change from tyrosine to phenylalanin at residue 47 (Y47F). SBT was performed for cloned DRB1*16-specific polymerase chain reaction fragment. The serological phenotype of DRB1*1609 is equivalent to DR16 antigen.
    No preview · Article · Oct 2005 · Tissue Antigens
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel HLA-B*07 allele, B*0740, has been identified by sequence-based typing (SBT) in the Chinese Han population. This new allele is identical to B*0705 and B*0706 for exons 2, 3, and 4, except for a single nucleotide at position 605 of codon 202 in exon 3 (AAG-->ATG) leading to an amino acid change from lysine to methionine. SBT was performed following allele separation using the Haploprep method. The serological equivalence of B*0740 to the B7 antigen did not change.
    No preview · Article · Aug 2005 · Tissue Antigens